Abstract
Background: Onychomycosis affects approximately one third of patients with diabetes. But, treatment failure risk of oral antifungal agents in diabetic patients is high due to poor patient compliance, drug interactions and decreased immune status. The neodymium-doped yttrium aluminum garnet (Nd:YAG) laser has recently been widely used as one of therapeutic options for onychomycosis. However, there have been few studies on clinical outcome of 1064-nm Nd:YAG laser treatment in diabetic patients.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call